Payment overview · 2025
General Payments
$779.67
36 reported records · 16 companies
Healthcare provider profile · identity verified
Michael Todd Warren, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DERIDDER, LA · NPI 1598114423
Verified facts
What the public records show
CMS Open Payments records show Michael Todd Warren, FNP received $779.67 in general payments during 2025 across 36 reported records.
Supernus Pharmaceuticals, Inc. accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $202.48 | 26.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $115.14 | 14.8% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $80.20 | 10.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.86 | 6.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $42.28 | 5.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.34 | 4.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.41 | 4.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.75 | 4.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $34.73 | 4.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.47 | 4.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.89 | 3.7% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $19.18 | 2.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.56 | 2.2% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $16.50 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.02 | 2.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.86 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $779.67 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $202.48 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $80.20 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $79.04 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.86 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.86 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.34 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.41 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.47 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 207 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
207 | 39 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 486 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 484 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 360 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 272 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 262 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 242 | 73 |
| Tizanidine Hcl | Tizanidine Hcl | 227 | 59 |
| Montelukast Sodium | Montelukast Sodium | 215 | 71 |
| Lisinopril | Lisinopril | 213 | 62 |
| Ozempic | Semaglutide | 207 | 39 |
| Furosemide | Furosemide | 188 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 56 |
| Omeprazole | Omeprazole | 169 | 51 |
| Diazepam | Diazepam | 164 | 29 |
| Metformin Hcl | Metformin Hcl | 164 | 45 |
| Losartan Potassium | Losartan Potassium | 161 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 44 |
| Potassium Chloride | Potassium Chloride | 157 | 40 |
| Prednisone | Prednisone | 147 | 98 |
| Meloxicam | Meloxicam | 146 | 60 |
| Alprazolam | Alprazolam | 132 | 30 |
| Trazodone Hcl | Trazodone Hcl | 128 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 120 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 114 | 30 |
| Clonazepam | Clonazepam | 113 | 27 |
| Famotidine | Famotidine | 111 | 25 |
| Carvedilol | Carvedilol | 109 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 43 |
| Sertraline Hcl | Sertraline Hcl | 100 | 29 |
| Azithromycin | Azithromycin | 97 | 78 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 22 |
| Allopurinol | Allopurinol | 94 | 23 |
| Temazepam | Temazepam | 94 | 13 |
| Ezetimibe | Ezetimibe | 93 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 32 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 91 | 24 |
| Tramadol Hcl | Tramadol Hcl | 89 | 29 |
| Jardiance | Empagliflozin | 88 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 86 | 27 |
| Eliquis | Apixaban | 83 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 63 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 67 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 25 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 61 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 12 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 60 | 15 |
| Aripiprazole | Aripiprazole | 59 | 19 |
| Ibuprofen | Ibuprofen | 59 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 35 |
| Glipizide | Glipizide | 52 | 13 |
| Mounjaro | Tirzepatide | 52 | 18 |
| Atenolol | Atenolol | 51 | 14 |
| Linzess | Linaclotide | 51 | 14 |
| Ondansetron Odt | Ondansetron | 50 | 18 |
| Celecoxib | Celecoxib | 49 | 14 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | 13 |
| Donepezil Hcl | Donepezil Hcl | 45 | 14 |
| Glimepiride | Glimepiride | 45 | 14 |
| Baclofen | Baclofen | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 18 |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 34 |
| Estradiol | Estradiol | 40 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 11 |
| Mirtazapine | Mirtazapine | 38 | 14 |
| Nifedipine Er | Nifedipine | 38 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 15 |
| Sucralfate | Sucralfate | 37 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 36 | 13 |
| Fluconazole | Fluconazole | 35 | 18 |
| Meclizine Hcl | Meclizine Hcl | 34 | 13 |
| Levofloxacin | Levofloxacin | 33 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 12 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 14 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | 11 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 24 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 12 |
| Mupirocin | Mupirocin | 28 | 15 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | 11 |
| Valsartan | Valsartan | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Zaleplon | Zaleplon | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $779.67 · 36 records | Supernus Pharmaceuticals, Inc. | BREZTRI, CAPLYTA, COBENFY, CeQur Simplicity, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, Jornay PM, Kerendia, OTEZLA, Ozempic, Qelbree, REPATHA, REXULTI, Rybelsus, VRAYLAR, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error